Fulcrum Shares Are Trading Higher As Candidate For Inherited Blood Disorders Shows Proof Of Mechanism, Biology In Early-Stage Study

  • Fulcrum Therapeutics Inc FULC has announced positive interim results from the Phase 1 trial with FTX-6058 in healthy adult volunteers. 
  • FTX-6058 is a potent and selective small-molecule inhibitor of EED designed to increase fetal hemoglobin (HbF) expression with the potential to treat hemoglobinopathies, such as sickle cell disease and beta-thalassemia. 
  • Results from the MAD portion of the trial demonstrated proof of biology as evidenced by a dose-proportional induction in HBG mRNA and accompanying increases in HbF-containing reticulocytes (F-reticulocytes). 
  • At 10mg, the highest dose studied to date, the mean changes were 4.5-fold and 4.2-fold, respectively.
  • Additionally, all FTX-6058 doses in the MAD portion of the trial achieved maximal target engagement by day seven in 6mg and 10mg cohorts.
  • Fulcrum plans to initiate a Phase 1b trial enrollment in sickle cell patients in 4Q 2021 and submit Investigational New Drug (IND) application in non-sickle cell hemoglobinopathies by year-end 2021.
  • As of 30 June, cash and marketable securities were $125.6 million, which will be sufficient to fund Fulcrum's expenses into Q1 of 2023.
  • Price Action: FULC shares are up 60.90% at $13.50 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLong IdeasNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefsPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!